Cargando…

Ensuring timely thromboprophylaxis on a Medical Assessment Unit

The Department of Health has defined hospital acquired venous thromboembolism (VTE) as any VTE event occurring within 90 days of hospital admission or surgery. (1) Hospital acquired thrombosis (HAT) is common during and after hospital admission and is considered a major patient safety issue. Current...

Descripción completa

Detalles Bibliográficos
Autores principales: Akinbobuyi, Oluwatosin, shalders, louise, Nokes, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: British Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5128761/
https://www.ncbi.nlm.nih.gov/pubmed/27933145
http://dx.doi.org/10.1136/bmjquality.u212414.w4934
_version_ 1782470467621224448
author Akinbobuyi, Oluwatosin
shalders, louise
Nokes, Tim
author_facet Akinbobuyi, Oluwatosin
shalders, louise
Nokes, Tim
author_sort Akinbobuyi, Oluwatosin
collection PubMed
description The Department of Health has defined hospital acquired venous thromboembolism (VTE) as any VTE event occurring within 90 days of hospital admission or surgery. (1) Hospital acquired thrombosis (HAT) is common during and after hospital admission and is considered a major patient safety issue. Current NICE guideline (CG 92) 2010, recommends that medical patients assessed at risk of VTE should have pharmacological prophylaxis commenced as soon as possible after risk assessment has been completed and continued until the patient is no longer at increased risk of VTE. (2) This quality improvement project was carried out in the medical assessment unit in Derriford Hospital, Plymouth. We aimed to increase appropriate VTE pharmacological prophylaxis to 100% prescribed in 6 hours by the end of May 2016 using the Plan-Do-Study-Act (PDSA) methodology. The primary outcome measure was whether or not enoxaparin was given within 6 hours of admission. Analysis showed that a major contributing factor to the prolonged time interval was lack of awareness of the Trust VTE guidelines which had recently been updated in accordance with NICE recommendations. Baseline measurement demonstrated that 29% of patients had first dose of enoxaparin within the 6-hour target, with a mean delay of 12 hours 22 minutes. With implementation of an education programme and development of a local VTE prevention care pathway to raise awareness of the new guidelines, a significant improvement was achieved with 71% of patients meeting the 6-hour target in PDSA cycle 1 and 83% of patients in PDSA cycle 2. The average time interval also reduced to 5 hours 52 minutes in PDSA cycle 1 and 5 hours 7 minutes in PDSA cycle 2. In conclusion, through utilization of simple change methodology, enoxaparin prescribing practice significantly improved. Potentially this may reduce morbidity (and mortality) associated with HAT together with cost implications of its management.
format Online
Article
Text
id pubmed-5128761
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher British Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-51287612016-12-08 Ensuring timely thromboprophylaxis on a Medical Assessment Unit Akinbobuyi, Oluwatosin shalders, louise Nokes, Tim BMJ Qual Improv Rep BMJ Quality Improvement Programme The Department of Health has defined hospital acquired venous thromboembolism (VTE) as any VTE event occurring within 90 days of hospital admission or surgery. (1) Hospital acquired thrombosis (HAT) is common during and after hospital admission and is considered a major patient safety issue. Current NICE guideline (CG 92) 2010, recommends that medical patients assessed at risk of VTE should have pharmacological prophylaxis commenced as soon as possible after risk assessment has been completed and continued until the patient is no longer at increased risk of VTE. (2) This quality improvement project was carried out in the medical assessment unit in Derriford Hospital, Plymouth. We aimed to increase appropriate VTE pharmacological prophylaxis to 100% prescribed in 6 hours by the end of May 2016 using the Plan-Do-Study-Act (PDSA) methodology. The primary outcome measure was whether or not enoxaparin was given within 6 hours of admission. Analysis showed that a major contributing factor to the prolonged time interval was lack of awareness of the Trust VTE guidelines which had recently been updated in accordance with NICE recommendations. Baseline measurement demonstrated that 29% of patients had first dose of enoxaparin within the 6-hour target, with a mean delay of 12 hours 22 minutes. With implementation of an education programme and development of a local VTE prevention care pathway to raise awareness of the new guidelines, a significant improvement was achieved with 71% of patients meeting the 6-hour target in PDSA cycle 1 and 83% of patients in PDSA cycle 2. The average time interval also reduced to 5 hours 52 minutes in PDSA cycle 1 and 5 hours 7 minutes in PDSA cycle 2. In conclusion, through utilization of simple change methodology, enoxaparin prescribing practice significantly improved. Potentially this may reduce morbidity (and mortality) associated with HAT together with cost implications of its management. British Publishing Group 2016-11-22 /pmc/articles/PMC5128761/ /pubmed/27933145 http://dx.doi.org/10.1136/bmjquality.u212414.w4934 Text en © 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/http://creativecommons.org/licenses/by-nc/2.0/legalcode
spellingShingle BMJ Quality Improvement Programme
Akinbobuyi, Oluwatosin
shalders, louise
Nokes, Tim
Ensuring timely thromboprophylaxis on a Medical Assessment Unit
title Ensuring timely thromboprophylaxis on a Medical Assessment Unit
title_full Ensuring timely thromboprophylaxis on a Medical Assessment Unit
title_fullStr Ensuring timely thromboprophylaxis on a Medical Assessment Unit
title_full_unstemmed Ensuring timely thromboprophylaxis on a Medical Assessment Unit
title_short Ensuring timely thromboprophylaxis on a Medical Assessment Unit
title_sort ensuring timely thromboprophylaxis on a medical assessment unit
topic BMJ Quality Improvement Programme
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5128761/
https://www.ncbi.nlm.nih.gov/pubmed/27933145
http://dx.doi.org/10.1136/bmjquality.u212414.w4934
work_keys_str_mv AT akinbobuyioluwatosin ensuringtimelythromboprophylaxisonamedicalassessmentunit
AT shalderslouise ensuringtimelythromboprophylaxisonamedicalassessmentunit
AT nokestim ensuringtimelythromboprophylaxisonamedicalassessmentunit